---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-273110"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:59:56.626154+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD raises $7M from Rubric Capital; extends debt maturity to Nov 30

## Summary
- Issued 7,000 shares of Series A Preferred Stock to Rubric Capital Management for $7M gross proceeds.
- Net proceeds to be used for working capital and general corporate purposes.
- Financing agreement maturity extended to Nov 30, 2022; lenders received warrants for 125k shares at $0.01.
- Warrants have a 10-year term and are exercisable via cashless exercise.
- Board and management continue to assess strategic alternatives to strengthen long-term financial position.

## SEC filing metadata
- accession: 0001193125-22-273110
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-273110
- JSON: https://secwatch.observer/filing/0001193125-22-273110.json
- Plain text: https://secwatch.observer/filing/0001193125-22-273110.txt

## Key facts
- Material Agreements
  TherapeuticsMD, Inc. entered into Subscription Agreement with Rubric Capital Management LP valued at $7 million (effective 2022-10-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Rubric Capital Management LP
  - Value: $7 million
  - Effective: 2022-10-28
  source text: On October 28, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company issued and sold, in a private placement offering (the “Offering”), 7,000 shares of the Company’s Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), for an aggregate offering price of $7 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm
- Material Agreements
  TherapeuticsMD, Inc. entered into Lender Subscription Agreement with the Lenders (effective 2022-10-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Lenders
  - Effective: 2022-10-28
  source text: on October 28, 2022 the Company issued warrants (the “Lender Warrants”), to the Lenders to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “Lender Subscription Agreement”), and the maturity date of the Financing Agreement was extended to November 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.